Javascript must be enabled to continue!
Paclitaxel loaded transfersomal vesicular drug delivery for the treatment of melanoma skin cancers
View through CrossRef
Over the last few years, there is tremendous growth of melanoma skin cancer in all around the world. Paclitaxel is an antineoplastic drug which is widely used for breast cancer, lung cancer, and Kaposi sarcoma. It is available only in the form of intravenous (IV), which produces tissue damage and hypersensitivity in some patients if the dose is over. In the present article, the new initiative formulation is done for melanoma skin cancer with transfersomes drug delivery systems. A different formulation of transfersomes is prepared using Span. The various characterization is done for the transfersomes like morphology, entrapment efficacy, in vitro drug release dialysis bag method. By using the Carbopol 940, the transfersomes gel was prepared. Paclitaxel-loaded transfersomes (FS-2) shows the positive entrapment efficacy 68.2% and the vesicle size 200 nm. From the in vitro dialysis bag method, FS-2 showed the high rate of drug release by nearly 72% in 12 hrs. we conclude that this will be the initial step for the further studies of melanoma skin cancer and provide the better treatment for skin cancer.
Title: Paclitaxel loaded transfersomal vesicular drug delivery for the treatment of melanoma skin cancers
Description:
Over the last few years, there is tremendous growth of melanoma skin cancer in all around the world.
Paclitaxel is an antineoplastic drug which is widely used for breast cancer, lung cancer, and Kaposi sarcoma.
It is available only in the form of intravenous (IV), which produces tissue damage and hypersensitivity in some patients if the dose is over.
In the present article, the new initiative formulation is done for melanoma skin cancer with transfersomes drug delivery systems.
A different formulation of transfersomes is prepared using Span.
The various characterization is done for the transfersomes like morphology, entrapment efficacy, in vitro drug release dialysis bag method.
By using the Carbopol 940, the transfersomes gel was prepared.
Paclitaxel-loaded transfersomes (FS-2) shows the positive entrapment efficacy 68.
2% and the vesicle size 200 nm.
From the in vitro dialysis bag method, FS-2 showed the high rate of drug release by nearly 72% in 12 hrs.
we conclude that this will be the initial step for the further studies of melanoma skin cancer and provide the better treatment for skin cancer.
Related Results
Abstract B14: A novel strategy for the treatment of melanoma
Abstract B14: A novel strategy for the treatment of melanoma
Abstract
Introduction: Approximately 76,000 individuals are diagnosed with melanoma, and about 9,000 die as a result of the disease each year in the United States. E...
Abstract B8: Caveolae-mediated endocytosis is critical for tumor cell response to nab-paclitaxel
Abstract B8: Caveolae-mediated endocytosis is critical for tumor cell response to nab-paclitaxel
Abstract
INTRODUCTION:
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and is typified by poor outcomes. G...
Abstract 1071: Efficacy of targeted osmotic lysis using pulsed electric field stimulation compared to paclitaxel for treating murine, triple-negative breast carcinoma
Abstract 1071: Efficacy of targeted osmotic lysis using pulsed electric field stimulation compared to paclitaxel for treating murine, triple-negative breast carcinoma
Abstract
Targeted osmotic lysis (TOL), the concurrent stimulation of voltage-gated sodium channels (VGSCs) and blockade of Na+ pumps, kills up to 100% of highly mali...
A Taxane Total Cost of Care Analysis in Metastatic Breast Cancer: Results of Private Payor Claims Data.
A Taxane Total Cost of Care Analysis in Metastatic Breast Cancer: Results of Private Payor Claims Data.
Abstract
Background: It has been estimated that over $8 billion is spent annually on the management of breast cancer in the US. The taxane chemotherapeutic agents ar...
Abstract 1585: Loss of CDK5 sensitizes ovarian cancer cells to paclitaxel by enhancing intracellular retention
Abstract 1585: Loss of CDK5 sensitizes ovarian cancer cells to paclitaxel by enhancing intracellular retention
Abstract
In order to improve the efficacy of paclitaxel in treatment of ovarian cancer, we have performed a kinome siRNA library screen to identify kinases that regu...
Abstract 1849: Determining the molecular requirements for paclitaxel-induced spindle multipolarity
Abstract 1849: Determining the molecular requirements for paclitaxel-induced spindle multipolarity
Abstract
Paclitaxel (TaxolTM) and other microtubule poisons are standard chemotherapy agents used in the treatment of breast cancer. However, only a subset of patien...
Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors
Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors
PURPOSE: To evaluate the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic (PK) profile of paclitaxel and carboplatin when administered every 3 wee...
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract
Background: The etiology of melanoma has generally been thought to be exposure to UV radiation (sun and sun tanning lamps). However, the percent of melanoma...

